In vitro assessment of spacers and valved holding chambers used with pressurized metered-dose inhalers: The need for a USP chapter with clinically relevant test methods

Pharmacopeial Forum

Volumn 37, Issue 4, 2011, Pages

  Mitchell, Jolyon P ^a   Poochikian, Guirag ^a   Hickey, Anthony J ^a   Suggett, Jason ^a   Curry, P D ^a   Tougas, Terrence P ^a   Zaidi, Kahkashan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AEROSOL; CANADA; FACE MASK; FLOW RATE; HEALTH CARE QUALITY; HUMAN; IN VITRO STUDY; INHALATION SPACER; INHALER; LABORATORY TEST; METERED DOSE INHALER; PARTICLE SIZE; PLUME; REVIEW; VALVED HOLDING CHAMBER;

EID: 80053147190     PISSN: 03634655     EISSN: 15421945     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Mitchell JP, Nagel MW. Valved holding chambers (VHCs) for use with pressurized metered-dose inhalers (pMDIs): a review of causes of inconsistent medication delivery. Primary Care Respir J. 2007;16(4):207-214. (Pubitemid 47281445)
2. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest. 2005;127(1):335-371.
3. Rubin BK, Fink JB. Optimizing aerosol delivery by pressurized metered-dose inhaler. Respir Care. 2005;50(9):1191-1200.
4. Dolovich MB. In my opinion: interview with the expert. Pediatr Asthma Allergy Immunol. 2004;17(4):292-300.
5. Fink JB. Metered-dose inhalers, dry powder inhalers, and transitions. Respir Care. 2000;45(6):623-635. (Pubitemid 30484802)
6. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and prevention. http://www.ginasthma.org. Accessed 17 January 2011.
7. Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease (COPD). http://www.goldcopd.org. Accessed 17 January 2011.
8. Health Canada. Release of draft guidance document: submission requirements for subsequent market entry inhaled corticosteroid products for use in the treatment of asthma. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/ applicdemande/guide-ld/inhal-corticost-eng.php. Published 01 August 2007. Accessed 17 January 2011.
9. European Medicines Agency. Requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents. http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003504.pdf. Updated 22 January 2009. Accessed 17 January 2011.
10. US Code of Federal Regulations. Title 21. Part 320.24(b) - Bioavailability and Bioequivalence Requirements. http://www.access.gpo.gov/nara/ cfr/waisidx-03/21cfr320-03.html. Accessed 17 January 2011.
11. FDA. CDER. Guidance for industry: metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products: chemistry, manufacturing, and controls documentation. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070573.pdf. Published October 1998. Accessed 17 January 2011.
12. Mitchell JP, Nagel MW. Spacer and holding chamber testing in vitro: a critical analysis with examples. In Dalby RN, Byron PR, Farr SJ, Peart J, eds. Respiratory Drug Delivery-VII. Raleigh, NC: Serentec Press, 2000:265-273.
13. Mitchell JP, Nagel MW. In vitro performance testing of three small volume valved holding chambers under conditions that correspond with use by infants and small children. J Aerosol Med. 1997;10(4):341-349. (Pubitemid 28006474)
14. CSA. Spacers and holding chambers for use with metered-dose inhalers. http://www.shopcsa.ca/onlinestore/GetCatalogItemDetails.asp?mat=2013981. Published 2002. Accessed 17 January 2011.
15. CSA. Spacers and holding chambers for use with metered-dose inhalers. http://www.shopcsa.ca/onlinestore/GetCatalogDrillDown.asp?Parent=3245. Revised 2008. Accessed 17 January 2011.
16. ISO. ISO 20072 Aerosol drug delivery device design verification- requirements and test methods. Geneva, Switzerland: ISO; 2009.
17. Dolovich MB, Mitchell JP. Canadian Standards Association standard CAN/CSA/Z264.1-02:2002: a new voluntary standard for spacers and holding chambers used with pressurized metered-dose inhalers. Can Respir J. 2004;11(7):489-495. (Pubitemid 39549460)
18. Bernstein JA, Amin H, Smith SJ. Therapeutic uses of lung aerosol. In: Hickey AJ, Ed. Inhalation Aerosols: Physical and Biological Basis for Therapy. New York, NY: Informa Healthcare; 2007:219-252.
19. Newman SP. Inhaler treatment options in COPD. Eur Respir Rev. 2005;14(96):102-108. (Pubitemid 43028767)
20. Boulet L-P, Becker A, Bérubé D, Beveridge R, Ernst P, Canadian Asthma Consensus Group. Canadian asthma consensus report, 1999. Can Med Assn J. 1999;161(11 Suppl):S1-S62.
21. Chapman KR, Voshaar TH, Virchow JC. Inhaler choice in primary practice. Eur Respir Rev. 2005;14(96):117-122. (Pubitemid 43028769)
22. Olson BA, Marple VA, Mitchell JP, Nagel MW. Development and calibration of a low-flow version of the Marple-Miller impactor. Aerosol Sci Technol. 1998;29:307-314. (Pubitemid 28433936)
23. Mitchell JP, Nagel MW. Cascade impactors for the size characterization of aerosols from medical inhalers: their use and limitations. J Aerosol Med. 2003;16:341-377. (Pubitemid 38120942)
24. Stocks J, Hislop AA. Structure and function of the respiratory system. In: Bisgaard H, O'Callaghan C, Smaldone GC, eds. Drug Delivery to the Lung. New York, NY: Marcel Dekker; 2002:47-104.
25. Mitchell, JP. Appropriate face models for evaluating drug delivery in infants and small children: the current situation and prospects for future advances. J Aerosol Med. 2008;21(1):97-111.
26. Shah SA, Berlinski A, Rubin BK. Force-dependent static dead space of face masks used with holding chambers. Respir Care. 2006;51(2):140-144. (Pubitemid 46888412)
27. Amirav, I. Infant aerosol holding chamber face masks: not all are born equal! Respir Care. 2006;51(2):123-125. (Pubitemid 46888409)
28. Esposito-Festen JE, Ates B, Van Vliet FLM, Verbraak AFM, De Jongste JC, Tiddens HAWM. Effect of a facemask leak on aerosol delivery from a pMDI-spacer system. J Aerosol Med. 2004;17(1):1-6. (Pubitemid 38520667)
29. Smaldone GC, Berg E, Nikander K. Variation in pediatric aerosol delivery: importance of facemask. J Aerosol Med. 2005;18:354-363. (Pubitemid 41395736)
30. Mitchell JP, Finlay JB, Nuttall JM, et al. Validation of a new model infant face with nasopharynx for the testing of valved holding chambers with facemask as a patient interface. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, eds. Respiratory Drug Delivery. River Grove, IL: Davis Healthcare International Publishing; 2010:777-780.